数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
研究问题
However, whether metformin attenuates LPS-induced pulmonary inflammation through coordinated remodeling of the gut microbiota and host-microbe metabolites remains insufficiently understood.
方法
Six-week-old SPF male C57BL/6J mice were obtained from GemPharmatech (Nanjing, China).；Mice were housed three per cage under specific pathogen-free conditions in a temperature-controlled room (21 ± 2 °C) with a 12 h light/dark cycle and free access to food and sterile drinking water.；Following a one-week acclimatization period, mice were randomly assigned to four groups: control (CON), LPS, metformin 200 mg/kg (MET 200 mg/kg), and metformin 400 mg/kg (MET 400 mg/kg).；Mice in the MET groups received metformin by oral gavage once daily for 7 days.
核心结论
These results identified a set of gut-serum synchronized metabolites associated with metformin-mediated improvement of lung inflammation, without establishing their colonic origin or causal role.；Histopathology and Immunostaining Lung and colon tissues were fixed in 10% neutral-buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E).；In the assessment of colonic-content samples, approximately 50 mg of sample was homogenized with 500 μL of 80% ice-cold methanol and incubated at –20 °C for 30 min. ‖ 结论：In conclusion, this study suggests that metformin alleviates LPS-induced pulmonary inflammation and colonic injury in association with coordinated remodeling of gut microbiota, intestinal luminal metabolites and circulating metabolites.
局限
The biological identity of several metformin-responsive metabolites provides plausible mechanistic clues for future studies.；The correlation networks were based on nominal p values and should be considered hypothesis-generating.；Future studies using metformin-only controls, post-LPS therapeutic dosing schedules, antibiotic depletion, fecal microbiota transplantation, germ-free animals, AMPK-pathway perturbation, isotope tracing, targeted metabolomics, and metabolite supplementation will be needed to test the causal structure and clinical translatability of this gut microbiota–metabolite–lung axis.
对本项目的价值
★★★★☆ 方法学进展决定我们能否在有限样本下检出真实效应，属基础设施级收益。命中核心 微生物组；设计 多组学。
全文来源
PMC JATS 全文（正文 37,534 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Multi-Omics Analysis Identifies Gut-Associated Metabolic Signatures Associated with Metformin-Mediated Protection Against LPS-Induced Lung Injury.
- 期刊与标识：Pharmaceuticals (Basel) · PMID 42943340 · DOI 10.3390/ph19101643**
B 级证据分级：B 级（同行评议临床前研究，主要为动物模型）
本文核心结论来自动物模型或体外细胞学，属临床前证据，不能外推至人体。「延长健康寿命」「改善功能」等表述在小鼠中的意义，与人类临床结局之间仍有距离。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。